Your session is about to expire
← Back to Search
Wearable Sensors for Blood Cancers
N/A
Recruiting
Led By Surbhi Sidana
Research Sponsored by Stanford University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 28 days
Awards & highlights
No Placebo-Only Group
Summary
This trial aims to monitor the effects of CAR-T cancer cell therapy and improve the management of side effects. The study will use wearable sensors to track patients' physiological changes, analyze their molecular profiles, and
Who is the study for?
This trial is for adults over 18 with Multiple Myeloma, Lymphoma, or Leukemia who are undergoing CAR-T cell therapy at Stanford University. Participants must speak English and be able to use wearable devices and collect blood samples with the help of a caregiver.
What is being tested?
The study tests if a Biostrap arm band can accurately monitor changes in patients' bodies during CAR-T therapy to manage side effects better. It also involves analyzing biological data (multiomic profile) alongside sensor and clinical data.
What are the potential side effects?
While not testing drugs directly, this trial monitors for adverse events like Cytokine Release Syndrome and neurotoxicity that may occur from the underlying CAR-T cancer treatment.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 28 days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~28 days
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Secondary study objectives
Microsampling
Safety of the microsampling device
Safety of wearable devices
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
3Treatment groups
Experimental Treatment
Active Control
Group I: Device physiological monitoringExperimental Treatment1 Intervention
Patients will receive wearable sensor devices (Biostrap arm band)
Group II: MicrosamplingActive Control1 Intervention
Blood microsamples will be collected at start of conditioning chemotherapy, daily while in the hospital, and after leaving the hospital and outpatient appointments.
Group III: Biostrap mobile AppActive Control1 Intervention
Data collection from wearable sensor.
Find a Location
Who is running the clinical trial?
Stanford UniversityLead Sponsor
2,491 Previous Clinical Trials
17,519,130 Total Patients Enrolled
12 Trials studying Multiple Myeloma
1,791 Patients Enrolled for Multiple Myeloma
Surbhi SidanaPrincipal InvestigatorStanford University
1 Previous Clinical Trials
30 Total Patients Enrolled
1 Trials studying Multiple Myeloma
30 Patients Enrolled for Multiple Myeloma